EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Controlled trial of calcitriol in hemodialysis patients



Controlled trial of calcitriol in hemodialysis patients



Clinical Nephrology 26(4): 185-191



We report on a 5-year, prospective, double-blind trial of 1,25 dihydroxycholecalciferol (calcitriol) versus placebo in 76 hemodialysis patients without biochemical or radiological evidence of bone disease. Calcitriol, 1 microgram daily, regularly induced hypercalcemia. Doses of 0.25 microgram daily or less proved satisfactory in most patients. During calcitriol treatment, plasma calcium concentration was significantly higher and serum parathyroid hormone concentration significantly lower than on placebo. There was no difference in the rates of development or of progression of vascular calcification in the two groups. Significantly more patients on placebo (17 vs. 6, p less than 0.05) developed a sustained elevation of plasma alkaline phosphatase concentration. Calcitriol appeared to protect against the development of histological evidence of osteitis fibrosa but not of osteomalacia, but accumulation of aluminum in bone occurred during the study. We conclude that calcitriol delays and may prevent the development of osteitis fibrosa in patients receiving regular hemodialysis and may reasonably be prescribed routinely in hemodialysis patients without biochemical or radiological abnormality, unless there is a substantial prospect of early renal transplantation.

(PDF emailed within 1 workday: $29.90)

Accession: 001554993

Download citation: RISBibTeXText

PMID: 3536232



Related references

A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients. Clinical Nephrology 54(4): 301-308, 2000

The NKF-NUS hemodialysis trial protocol - a randomized controlled trial to determine the effectiveness of a self management intervention for hemodialysis patients. Bmc Nephrology 12(): 4-4, 2011

Oral pulse calcitriol versus intravenous calcitriol therapy in treatment of hyperparathyrodism in hemodialysis patients. Journal of the American Society of Nephrology 5(3): 889, 1994

Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial. Clinical Nephrology 71(6): 660-668, 2009

Intravenous calcitriol therapy in severe secondary hyperparathyroidism of adult hemodialysis patients non-responders to oral calcitriol treatment. Nephrology Dialysis Transplantation 13(6): A37, June, 1998

Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism. Therapeutic Apheresis and Dialysis 11(3): 202-209, 2007

Suppressive effects of intravenous calcitriol on secondary hyperparathyroidism of hemodialysis patients A double blind comparative trial among 4 doses. Journal of the American Society of Nephrology 5(3): 876, 1994

Prospective randomized trial comparing calcium carbonate , with oral and intravenous calcitriol in hemodialysis patients with uremic hyperparathyroidism. Journal of the American Society of Nephrology 9(PROGRAM AND ABSTR ISSUE): 575A, Sept, 1997

Effect of calcitriol in the control of plasma calcium after parathyroidectomy. A placebo-controlled, double-blind study in chronic hemodialysis patients. Nephron 46(1): 18-22, 1987

Controlled trial of calcitriol in the prevention of bone disease in haemodialysed patients. Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association 19: 287-292, 1983

Comparison of the effects of calcitriol and maxacalcitol on the secondary hyperparathyroidism in the patients on chronic hemodialysis therapy A randomized prospective multicenter Trial. Journal of the American Society of Nephrology 14(Abstracts Issue): 201A, November, 2003

Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial. American Journal of Kidney Diseases 59(1): 67-74, 2012

Comparison of intermittent intravenous and oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients: a meta-analysis of randomized controlled trials. Clinical Nephrology 71(3): 276-285, 2009

Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney International 42(5): 1191-1198, 1992

Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial. Canadian Journal of Clinical Pharmacology 15(1): E36-E43, 2008